Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rockwell Medical, Inc. (RMTI)
USD5.68
+0.05 (+0.88%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
30142 South Wixom road 48393
Wixom, MI, US
Wixom, MI, US
CEO
Mark Strobeck
Website
rockwellmed.com
IPO
1998-01-27
CIK 1041024 ISIN US7743744093
Description
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.68
+0.05 (+0.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31.6K
Beta
1.62
Float Shares
34.15M
Free Float %
86.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.57% | +5.72% | -7.32% | -17.33% | -11.72% | +1.16% | -18.92% | -65.58% | -91.67% | -99.04% | -98.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
5.68
Low
3.00
-47.2%
Consensus
3.00
-47.2%
Median
3.00
-47.2%
High
3.00
-47.2%
DCF (Unlevered)
690.49
+12,056.9%
DCF (Levered)
690.01
+12,048.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 3 |
7.67
+35.0%
|
Quality scores
Altman Z-Score
209.15
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-31.8% Q1'26: +91,557.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-495.2% Q1'26: +8.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-8.3% Q1'26: 0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-6.8% Q1'26: -8.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: -22,460.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+15.8% Q1'26: +15.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.99× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
52.38M
est: 46.34M (+13.0%)
|
54.19M
est: 50.28M (+7.8%)
|
55.35M
est: 60.49M (-8.5%)
|
53.28M
est: 54.73M (-2.6%)
|
57.30M
est: 56.16M (+2.0%)
|
63.39M
est: 62.63M (+1.2%)
|
61.30M
est: 62.03M (-1.2%)
|
62.20M
est: 62.73M (-0.8%)
|
61.93M
est: 64.25M (-3.6%)
|
72.81M
est: 69.80M (+4.3%)
|
83.61M
est: 94.37M (-11.4%)
|
101.49M
est: 100.32M (+1.2%)
|
69.26M
est: 69.51M (-0.4%)
|
73.77M
72.55M – 74.99M
+6.1% YoY
|
79.99M
78.67M – 81.31M
+8.4% YoY
|
75.60M
74.35M – 76.85M
-5.5% YoY
|
81.60M
80.25M – 82.95M
+7.9% YoY
|
| EBITDA |
-45.95M
est: -33.54M (-37.0%)
|
-16.18M
est: -11.71M (-38.1%)
|
-13.60M
est: -48.91M (+72.2%)
|
-18.64M
est: -12.34M (-51.0%)
|
-25.41M
est: -12.67M (-100.6%)
|
-31.48M
est: -14.13M (-122.8%)
|
-31.48M
est: -13.99M (-125.0%)
|
-26.72M
est: -14.15M (-88.9%)
|
-27.80M
est: -14.49M (-91.9%)
|
-16.17M
est: -58.41M (+72.3%)
|
-4.69M
est: -13.85M (+66.1%)
|
2.95M
est: -14.73M (+120.1%)
|
-2.50M
est: -10.20M (+75.5%)
|
-10.83M
-11.01M – -10.65M
-6.1% YoY
|
-11.74M
-11.94M – -11.55M
-8.4% YoY
|
-11.10M
-11.28M – -10.92M
+5.5% YoY
|
-11.98M
-12.18M – -11.78M
-7.9% YoY
|
| EBIT |
-46.96M
est: -34.45M (-36.3%)
|
-17.17M
est: -12.83M (-33.9%)
|
-14.42M
est: -53.61M (+73.1%)
|
-19.40M
est: -13.70M (-41.6%)
|
-25.92M
est: -14.06M (-84.4%)
|
-31.41M
est: -15.68M (-100.3%)
|
-34.10M
est: -15.53M (-119.6%)
|
-29.01M
est: -15.70M (-84.8%)
|
-30.31M
est: -16.08M (-88.5%)
|
-16.74M
est: -62.55M (+73.2%)
|
-6.14M
est: -16.10M (+61.9%)
|
774.0K
est: -17.11M (+104.5%)
|
-4.69M
est: -11.86M (+60.4%)
|
-12.58M
-12.79M – -12.38M
-6.1% YoY
|
-13.65M
-13.87M – -13.42M
-8.4% YoY
|
-12.90M
-13.11M – -12.68M
+5.5% YoY
|
-13.92M
-14.15M – -13.69M
-7.9% YoY
|
| Net Income |
-48.78M
est: -36.05M (-35.3%)
|
-21.33M
est: -15.78M (-35.1%)
|
-14.42M
est: -51.11M (+71.8%)
|
-19.80M
est: -102.49M (+80.7%)
|
-25.92M
est: -121.28M (+78.6%)
|
-32.13M
est: -194.74M (+83.5%)
|
-34.13M
est: -195.88M (+82.6%)
|
-30.89M
est: -134.95M (+77.1%)
|
-32.67M
est: -116.16M (+71.9%)
|
-18.68M
est: -11.61M (-60.9%)
|
-8.44M
est: -5.71M (-47.9%)
|
-480.0K
est: 359.7K (-233.4%)
|
-5.31M
est: -4.14M (-28.5%)
|
-2.70M
-2.76M – -2.64M
+34.8% YoY
|
-359.7K
-367.5K – -352.0K
+86.7% YoY
|
1.44M
1.41M – 1.47M
+500.0% YoY
|
5.04M
4.93M – 5.14M
+250.0% YoY
|
| SGA |
14.34M
est: 11.45M (+25.3%)
|
18.32M
est: 14.73M (+24.4%)
|
19.08M
est: 58.05M (-67.1%)
|
21.12M
est: 14.31M (+47.6%)
|
23.30M
est: 14.69M (+58.7%)
|
23.08M
est: 16.38M (+40.9%)
|
30.05M
est: 16.22M (+85.2%)
|
24.05M
est: 16.40M (+46.6%)
|
21.08M
est: 16.80M (+25.5%)
|
17.74M
est: 55.98M (-68.3%)
|
14.27M
est: 4.48B (-99.7%)
|
16.86M
est: 4.77B (-99.6%)
|
16.39B
est: 3.30B (+396.3%)
|
3.50B
3.45B – 3.56B
+6.1% YoY
|
3.80B
3.74B – 3.86B
+8.4% YoY
|
3.59B
3.53B – 3.65B
-5.5% YoY
|
3.88B
3.81B – 3.94B
+7.9% YoY
|
| EPS |
-16.32
est: -0.99 (-1,556.9%)
|
-5.72
est: -0.38 (-1,425.3%)
|
-3.19
est: -1.47 (-116.4%)
|
-4.30
est: -3.30 (-30.3%)
|
-5.61
est: -3.91 (-43.7%)
|
-6.69
est: -6.27 (-6.7%)
|
-5.61
est: -6.31 (+11.0%)
|
-4.49
est: -4.35 (-3.3%)
|
-3.83
est: -3.74 (-2.4%)
|
-1.89
est: -2.12 (+10.8%)
|
-0.36
est: -0.16 (-127.0%)
|
-0.03
est: 0.01 (-352.0%)
|
-0.15
est: -0.12 (-30.4%)
|
-0.08
-0.08 – -0.07
+34.8% YoY
|
-0.01
-0.01 – -0.01
+86.7% YoY
|
0.04
0.04 – 0.04
+500.0% YoY
|
0.14
0.14 – 0.14
+250.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.74B
OE per share TTM
44.02
Owner's Yield
5,636.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
106.9K
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DaVita Inc. | 7.50M | 7.40% | 7.50M | — | 7.50M | — | HC, CO | Delaware | 2022-04-18 | ↗ |
| 2 | CVI Investments, Inc. | 4.91M | 4.90% | — | 4.91M | — | 4.91M | CO | Cayman Islands | 2021-02-16 | ↗ |
| 3 | Heights Capital Management, Inc. | 4.91M | 4.90% | — | 4.91M | — | 4.91M | CO | Cayman Islands | 2021-02-16 | ↗ |
| 4 | Armistice Capital Master Fund Ltd. | 4.84M | 4.99% | — | 4.84M | — | 4.84M | CO | Delaware | 2020-10-02 | ↗ |
| 5 | Armistice Capital, LLC | 1.22M | 9.99% | — | 1.22M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 6 | Steven Boyd | 1.22M | 9.99% | — | 1.22M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 7 | Matthew J. Curfman | 994.4K | 8.55% | 480.0K | — | 480.0K | 514.4K | IN | USA | 2023-02-23 | ↗ |
| 8 | David S. Richmond | 991.0K | 8.52% | 476.6K | — | 476.6K | 514.4K | IN | USA | 2023-02-23 | ↗ |
| 9 | (1) BlackRock, Inc. | 959.9K | 1.00% | 959.9K | — | 959.9K | — | HC | Delaware | 2022-02-24 | ↗ |
| 10 | Richmond Brothers, Inc. | 520.0K | 4.47% | 5.6K | — | 5.6K | 514.4K | IA, CO | MICHIGAN | 2023-02-23 | ↗ |
| 11 | Mark H. Ravich | 467.7K | 1.00% | 467.7K | — | 467.7K | 10.00 | IN | USA | 2017-03-23 | ↗ |
| 12 | The RBI Opportunities Fund I, LLC | 315.1K | 2.70% | 315.1K | — | 315.1K | — | OO | DELAWARE | 2023-02-23 | ↗ |
| 13 | RBI PI Manager, LLC | 194.6K | 1.00% | 194.6K | — | 194.6K | 10.00 | OO | DELAWARE | 2017-03-23 | ↗ |
| 14 | The RBI Opportunities Fund II, LLC | 130.3K | 1.10% | 130.3K | — | 130.3K | — | OO | DELAWARE | 2023-02-23 | ↗ |
| 15 | Norman J. Ravich Irrevocable Trust | 44.4K | 1.00% | 44.4K | — | 44.4K | 10.00 | OO | MINNESOTA | 2017-03-23 | ↗ |
| 16 | Alexander Coleman Ravich 1991 Irrevocable Trust | 25.0K | 1.00% | 25.0K | — | 25.0K | 10.00 | OO | MINNESOTA | 2017-03-23 | ↗ |
| 17 | Alyssa Danielle Ravich 1991 Irrevocable Trust | 25.0K | 1.00% | 25.0K | — | 25.0K | 10.00 | OO | MINNESOTA | 2017-03-23 | ↗ |
| 18 | Norman and Sally Ravich Family Trust | 18.5K | 1.00% | 18.5K | — | 18.5K | 10.00 | OO | MINNESOTA | 2017-03-23 | ↗ |
| 19 | Richmond Brothers 401(k) Profit Sharing Plan | 11.4K | 1.00% | 11.4K | — | 11.4K | — | EP | MICHIGAN | 2023-02-23 | ↗ |
| 20 | RBI Private Investment I, LLC | 5.9K | 1.00% | 5.9K | — | 5.9K | — | OO | DELAWARE | 2023-02-23 | ↗ |
| 21 | RBI Private Investment II, LLC | 3.5K | 1.00% | 3.5K | — | 3.5K | — | OO | DELAWARE | 2023-02-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-32 vs prev Q
New positions
0
Closed positions
31
Increased
1
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1.40M +42.8K (+3.2%) | 1.17M -459.9K (-28.3%) | 3.88% -0.069 pp | 0.00% +0.000 pp | USD1.88 -55.9% | 15 qtrs — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 468.3K -93.9K (-16.7%) | 390.3K -284.3K (-42.1%) | 1.30% -0.339 pp | 0.00% 0.000 pp | USD1.79 -53.6% | 15 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 364.8K +41.7K (+12.9%) | 304.1K -83.7K (-21.6%) | 1.01% +0.071 pp | 0.00% +0.000 pp | USD2.16 -61.6% | 15 qtrs — |
| 4 | BLACKROCK, INC. | 220.7K -1.5K (-0.7%) | 183.9K -82.6K (-31.0%) | 0.61% -0.035 pp | 0.00% +0.000 pp | USD3.70 -77.6% | 6 qtrs — |
| 5 | UBS GROUP AG | 139.7K +132.2K (+1,749.8%) | 116.5K +107.5K (+1,185.6%) | 0.39% +0.366 pp | 0.00% +0.000 pp | USD1.00 -17.0% | 14 qtrs — |
| 6 | NORTHERN TRUST CORP | 102.4K +20.3K (+24.7%) | 85.3K -13.2K (-13.4%) | 0.28% +0.045 pp | 0.00% +0.000 pp | USD1.64 -49.4% | 15 qtrs — |
| 7 | JANE STREET GROUP, LLC | 101.1K +101.1K (+100.0%) | 84.2K +84.2K (+100.0%) | 0.28% +0.281 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 100.9K +— (+0.0%) | 84.1K -37.0K (-30.5%) | 0.28% -0.014 pp | 0.00% +0.000 pp | USD2.12 -60.8% | 15 qtrs — |
| 9 | HIGHTOWER ADVISORS, LLC | 93.5K +— (+0.0%) | 78.0K -34.3K (-30.5%) | 0.26% -0.013 pp | 0.00% +0.000 pp | USD2.10 -60.5% | 10 qtrs — |
| 10 | PERKINS CAPITAL MANAGEMENT INC | 67.9K -4.1K (-5.6%) | 56.6K -29.7K (-34.5%) | 0.19% -0.021 pp | 0.04% -0.031 pp | USD1.76 -52.8% | 15 qtrs — |
| 11 | PANAGORA ASSET MANAGEMENT INC | 67.3K -1.3K (-1.9%) | 56.1K -26.2K (-31.9%) | 0.19% -0.013 pp | 0.00% 0.000 pp | USD0.95 -12.6% | 3 qtrs — |
| 12 | XTX TOPCO LTD | 62.1K +46.0K (+286.5%) | 51.8K +32.5K (+168.4%) | 0.17% +0.126 pp | 0.00% +0.000 pp | USD0.93 -10.8% | 2 qtrs — |
| 13 | CITADEL ADVISORS LLC | 43.8K +43.8K (+100.0%) | 36.5K +36.5K (+100.0%) | 0.12% +0.122 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 13 qtrs — |
| 14 | LPL FINANCIAL LLC | 41.7K -3.8K (-8.3%) | 34.8K -19.8K (-36.3%) | 0.12% -0.017 pp | 0.00% +0.000 pp | USD2.72 -69.5% | 6 qtrs — |
| 15 | WEALTHTRUST AXIOM LLC | 37.9K +7.2K (+23.5%) | 31.6K -5.3K (-14.3%) | 0.11% +0.016 pp | 0.01% -0.002 pp | USD1.84 -54.9% | 10 qtrs — |
| 16 | TWO SIGMA SECURITIES, LLC | 34.2K +2.8K (+8.9%) | 28.5K -9.2K (-24.4%) | 0.09% +0.003 pp | 0.00% -0.002 pp | USD1.44 -42.4% | 5 qtrs — |
| 17 | RICHMOND BROTHERS, INC. | 30.6K -194.0 (-0.6%) | 25.5K -11.5K (-31.0%) | 0.09% -0.005 pp | 0.02% -0.007 pp | USD1.29 -35.7% | 15 qtrs — |
| 18 | BEACON FINANCIAL ADVISORY LLC | 24.6K +— (+0.0%) | 20.5K -9.0K (-30.5%) | 0.07% -0.003 pp | 0.00% -0.002 pp | USD3.97 -79.1% | 6 qtrs — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 21.3K -4.3K (-16.8%) | 17.7K -13.0K (-42.5%) | 0.06% -0.016 pp | 0.00% +0.000 pp | USD1.20 -30.8% | 2 qtrs — |
| 20 | BURFORD BROTHERS, INC. | 14.2K +— (+0.0%) | 11.8K -5.2K (-30.5%) | 0.04% -0.002 pp | 0.00% -0.002 pp | USD0.85 -2.4% | 3 qtrs — |
| 21 | MUTUAL ADVISORS, LLC | 12.0K +12.0K (+100.0%) | 10.0K +10.0K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 1 qtrs NEW |
| 22 | COMMONWEALTH EQUITY SERVICES, LLC | 10.1K +45.0 (+0.4%) | 8.4K -3.6K (-29.7%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.20 -30.8% | 2 qtrs — |
| 23 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.5K +6.5K (+100.0%) | 5.4K +5.4K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 15 qtrs — |
| 24 | WELLS FARGO & COMPANY/MN | 5.0K +— (+0.0%) | 4.2K -1.8K (-30.5%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.79 -70.3% | 15 qtrs — |
| 25 | MORGAN STANLEY | 3.5K -5.9K (-62.4%) | 3.0K -8.3K (-73.9%) | 0.01% -0.018 pp | 0.00% +0.000 pp | USD1.66 -50.0% | 15 qtrs — |
| 26 | SIMPLEX TRADING, LLC | 2.3K +860.0 (+60.9%) | 1.9K +895.0 (+89.5%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD0.84 -1.2% | 3 qtrs — |
| 27 | — | 1.4K +1.4K (+100.0%) | 1.2K +1.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 1 qtrs NEW |
| 28 | BANK OF AMERICA CORP /DE/ | 575.00 -7.8K (-93.1%) | 478.00 -9.6K (-95.2%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD1.29 -35.7% | 13 qtrs — |
| 29 | FORTITUDE FAMILY OFFICE, LLC | 495.00 +495.0 (+100.0%) | 413.00 +413.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.83 +0.0% | 1 qtrs NEW |
| 30 | ADVISOR GROUP HOLDINGS, INC. | 461.00 +14.0 (+3.1%) | 381.00 -293.0 (-43.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.10 -60.5% | 15 qtrs — |
| 31 | VERMILLION WEALTH MANAGEMENT, INC. | 360.00 +— (+0.0%) | 300.00 -132.0 (-30.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.04 -59.3% | 5 qtrs — |
| 32 | SBI SECURITIES CO., LTD. | 360.00 -3.2K (-89.7%) | 300.00 -3.9K (-92.9%) | 0.00% -0.009 pp | 0.00% 0.000 pp | USD2.01 -58.7% | 5 qtrs — |
| 33 | JONES FINANCIAL COMPANIES LLLP | 258.00 -1.0K (-79.5%) | 215.00 -1.4K (-86.5%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.85 -55.1% | 5 qtrs — |
| 34 | COMERICA BANK | 163.00 +— (+0.0%) | 136.00 -60.0 (-30.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.08 -60.1% | 10 qtrs — |
| 35 | JPMORGAN CHASE & CO | 35.00 +— (+0.0%) | 29.00 -13.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.94 -78.9% | 11 qtrs — |
| 36 | GROUP ONE TRADING, L.P. | 12.00 +— (+0.0%) | 10.00 -4.0 (-28.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.17 -29.1% | 2 qtrs — |
| 37 | FMR LLC | 6.00 +— (+0.0%) | 5.00 -3.0 (-37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.17 -29.1% | 5 qtrs — |
| 38 | RAYMOND JAMES FINANCIAL INC | — -13.4K (-100.0%) | — -16.1K (-100.0%) | 0.00% -0.039 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 39 | SKYOAK WEALTH, LLC | — -12.3K (-100.0%) | — -14.8K (-100.0%) | 0.00% -0.036 pp | 0.00% -0.003 pp | USD— | 15 qtrs SOLD |
| 40 | GSA CAPITAL PARTNERS LLP | — -164.0K (-100.0%) | — -197.0K (-100.0%) | 0.00% -0.478 pp | 0.00% -0.016 pp | USD— | 7 qtrs SOLD |
| 41 | CORSAIR CAPITAL MANAGEMENT, L.P. | — -35.0K (-100.0%) | — -42.0K (-100.0%) | 0.00% -0.102 pp | 0.00% -0.007 pp | USD— | 6 qtrs SOLD |
| 42 | WEALTHSPIRE ADVISORS, LLC | — -10.0K (-100.0%) | — -12.1K (-100.0%) | 0.00% -0.029 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 43 | BARCLAYS PLC | — -22.6K (-100.0%) | — -89.8K (-100.0%) | 0.00% -0.066 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 44 | RISE ADVISORS, LLC | — -215.0 (-100.0%) | — -258.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 15 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 261.0K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.3K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.4K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 254.40 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 588.6K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.3K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 701.95 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 283.56 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 31.25 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 4.40 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
7
Shares acquired
—
Shares disposed
22.1K
Cash buys
—
Cash sales
2.00
Net activity
-22,086
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-14 | TIMMINS MEGAN C. | Officer | F-InKind | D | Common Stock | 3,667 | 0.90 | 3.3K | 162,408 | D | ↗ |
| 2026-03-14 | Strobeck Mark | Director / Officer | F-InKind | D | Common Stock | 7,333 | 0.90 | 6.6K | 323,493 | D | ↗ |
| 2026-03-14 | Neri Jesse | Officer | F-InKind | D | Common Stock | 2,444 | 0.90 | 2.2K | 122,398 | D | ↗ |
| 2026-03-14 | Hunter Heather | Officer | F-InKind | D | Common Stock | 2,444 | 0.90 | 2.2K | 130,079 | D | ↗ |
| 2026-03-14 | Chole Timothy | Officer | F-InKind | D | Common Stock | 2,444 | 0.90 | 2.2K | 122,855 | D | ↗ |
| 2026-01-02 | Neri Jesse | Officer | S-Sale | D | Common Stock | 886 | 0.84 | 740.25 | 124,842 | D | ↗ |
| 2026-01-02 | Hunter Heather | Officer | S-Sale | D | Common Stock | 2,868 | 0.84 | 2.4K | 132,523 | D | ↗ |
| 2025-11-18 | COOPER JOHN G | Director | S-Sale | D | Common Stock | 5,079 | 0.87 | 4.4K | 140,372 | D | ↗ |
| 2025-11-17 | Dawson Joseph H | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-10-01 | Strobeck Mark | Director / Officer | S-Sale | D | Common Stock | 6,926 | 1.19 | 8.2K | 330,826 | D | ↗ |
| 2025-10-01 | Neri Jesse | Officer | S-Sale | D | Common Stock | 886 | 1.19 | 1.1K | 125,728 | D | ↗ |
| 2025-10-01 | Hunter Heather | Officer | S-Sale | D | Common Stock | 2,868 | 1.19 | 3.4K | 135,391 | D | ↗ |
| 2025-10-01 | Chole Timothy | Officer | S-Sale | D | Common Stock | 2,868 | 1.19 | 3.4K | 125,299 | D | ↗ |
| 2025-09-23 | Hunter Heather | Officer | — | — | Common Stock | 0 | 0.00 | — | 138,259 | D | ↗ |
| 2025-07-01 | Strobeck Mark | Director / Officer | S-Sale | D | Common Stock | 6,926 | 0.82 | 5.7K | 337,752 | D | ↗ |
| 2025-07-01 | Neri Jesse | Officer | S-Sale | D | Common Stock | 886 | 0.82 | 726.52 | 126,614 | D | ↗ |
| 2025-07-01 | Chole Timothy | Officer | S-Sale | D | Common Stock | 2,868 | 0.82 | 2.4K | 128,167 | D | ↗ |
| 2025-05-20 | TIMMINS MEGAN C. | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 1.07 | 208.7K | 195,000 | D | ↗ |
| 2025-05-20 | Strobeck Mark | Director / Officer | A-Award | A | Common Stock | 220,000 | 0.00 | — | 344,678 | D | ↗ |
| 2025-05-20 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 142,062 | D | ↗ |
| 2025-05-20 | Radie Robert S | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 143,525 | D | ↗ |
| 2025-05-20 | RAVICH MARK H | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 148,831 | D | ↗ |
| 2025-05-20 | Nissenson Allen | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 142,597 | D | ↗ |
| 2025-05-20 | Neri Jesse | Officer | A-Award | A | Common Stock | 97,500 | 0.00 | — | 127,500 | D | ↗ |
| 2025-05-20 | Lau Joan | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 113,111 | D | ↗ |
| 2025-05-20 | Chole Timothy | Officer | A-Award | A | Common Stock | 85,000 | 0.00 | — | 131,035 | D | ↗ |
| 2025-05-20 | COOPER JOHN G | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 145,451 | D | ↗ |
| 2025-04-11 | Irrevocable Larson Family Investment Trust | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 1.08 | 2.2K | 3,538,000 | D | ↗ |
| 2025-04-10 | Irrevocable Larson Family Investment Trust | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 1.10 | 11.0K | 3,509,000 | D | ↗ |
| 2025-04-01 | Strobeck Mark | Director / Officer | S-Sale | D | Common Stock | 6,926 | 1.08 | 7.5K | 124,678 | D | ↗ |
| 2025-04-01 | Neri Jesse | Officer | S-Sale | D | Common Stock | 886 | 1.10 | 974.60 | 30,000 | D | ↗ |
| 2025-04-01 | Chole Timothy | Officer | S-Sale | D | Common Stock | 2,868 | 1.08 | 3.1K | 46,035 | D | ↗ |
| 2025-03-17 | TIMMINS MEGAN C. | Officer | F-InKind | D | Common Stock | 3,137 | 1.77 | 5.6K | 68,575 | D | ↗ |
| 2025-03-17 | Strobeck Mark | Director / Officer | F-InKind | D | Common Stock | 6,101 | 1.77 | 10.8K | 131,604 | D | ↗ |
| 2025-03-17 | Chole Timothy | Officer | F-InKind | D | Common Stock | 2,823 | 1.77 | 5.0K | 48,903 | D | ↗ |
| 2025-03-14 | TIMMINS MEGAN C. | Officer | F-InKind | D | Common Stock | 3,666 | 1.70 | 6.2K | 71,712 | D | ↗ |
| 2025-03-14 | Strobeck Mark | Director / Officer | F-InKind | D | Common Stock | 7,333 | 1.70 | 12.5K | 137,705 | D | ↗ |
| 2025-03-14 | Neri Jesse | Officer | F-InKind | D | Common Stock | 2,444 | 1.70 | 4.2K | 30,886 | D | ↗ |
| 2025-03-14 | Chole Timothy | Officer | F-InKind | D | Common Stock | 2,444 | 1.70 | 4.2K | 51,726 | D | ↗ |
| 2025-01-02 | Strobeck Mark | Director / Officer | S-Sale | D | Common Stock | 2,163 | 2.06 | 4.4K | 145,038 | D | ↗ |
| 2025-01-02 | Chole Timothy | Officer | S-Sale | D | Common Stock | 1,001 | 2.05 | 2.1K | 54,170 | D | ↗ |
| 2024-12-12 | Irrevocable Larson Family Investment Trust | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 3,462,500 | D | ↗ |
| 2024-11-15 | RAVICH MARK H | Director | S-Sale | D | Common Stock | 10,000 | 2.40 | 24.0K | 121,429 | D | ↗ |
| 2024-10-01 | Strobeck Mark | Director / Officer | S-Sale | D | Common Stock | 2,163 | 3.69 | 8.0K | 147,201 | D | ↗ |
| 2024-10-01 | Chole Timothy | Officer | S-Sale | D | Common Stock | 1,001 | 3.69 | 3.7K | 55,171 | D | ↗ |
| 2024-05-21 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 92,062 | — | ↗ |
| 2024-05-21 | Radie Robert S | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 93,525 | — | ↗ |
| 2024-05-21 | RAVICH MARK H | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 108,831 | — | ↗ |
| 2024-05-21 | Nissenson Allen | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 92,597 | — | ↗ |
| 2024-05-21 | Lau Joan | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 63,111 | — | ↗ |
| 2024-05-21 | Chole Timothy | Officer | — | D | Non-Qualified Stock Options | 47,190 | 1.39 | 65.6K | 0 | — | ↗ |
| 2024-05-21 | COOPER JOHN G | Director | A-Award | A | Common Stock | 36,111 | 0.00 | — | 95,451 | — | ↗ |
| 2024-03-17 | TIMMINS MEGAN C. | Officer | F-InKind | D | Common Stock | 3,137 | 1.40 | 4.4K | 75,378 | — | ↗ |
| 2024-03-17 | Strobeck Mark | Director / Officer | F-InKind | D | Common Stock | 6,101 | 1.40 | 8.5K | 149,364 | — | ↗ |
| 2024-03-14 | TIMMINS MEGAN C. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 78,515 | — | ↗ |
| 2024-03-14 | Strobeck Mark | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 155,465 | — | ↗ |
| 2024-03-14 | Neri Jesse | Officer | A-Award | A | Stock Option (Right to Buy) | 47,190 | 1.39 | 65.6K | 47,190 | — | ↗ |
| 2023-10-16 | Neri Jesse | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-16 | Lau Joan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-23 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 24,715 | 0.00 | — | 118,316 | — | ↗ |
| 2023-05-23 | Radie Robert S | Director | A-Award | A | Common Stock | 24,715 | 0.00 | — | 134,404 | — | ↗ |
| 2023-05-23 | RAVICH MARK H | Director | A-Award | A | Common Stock | 24,715 | 0.00 | — | 303,319 | — | ↗ |
| 2023-05-23 | Nissenson Allen | Director | A-Award | A | Common Stock | 24,715 | 0.00 | — | 124,203 | — | ↗ |
| 2023-05-23 | COOPER JOHN G | Director | A-Award | A | Common Stock | 24,715 | 0.00 | — | 155,594 | — | ↗ |
| 2023-03-17 | TIMMINS MEGAN C. | Officer | A-Award | A | Common Stock | 28,515 | 0.00 | — | 28,515 | — | ↗ |
| 2023-03-17 | Strobeck Mark | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 77,105 | 1.37 | 105.6K | 77,105 | — | ↗ |
| 2023-03-17 | McGarry Paul E | Officer | A-Award | A | Common Stock | 28,515 | 0.00 | — | 28,515 | — | ↗ |
| 2023-03-17 | Hoffman Marc L | Officer | A-Award | A | Common Stock | 25,665 | 0.00 | — | 25,665 | — | ↗ |
| 2022-09-09 | TIMMINS MEGAN C. | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 1.66 | 132.8K | 80,000 | — | ↗ |
| 2022-09-09 | SKIBSTED RUSSELL | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 1.66 | 132.8K | 80,000 | — | ↗ |
| 2022-09-09 | McGarry Paul E | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.66 | 99.6K | 60,000 | — | ↗ |
| 2022-09-09 | Hoffman Marc L | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.66 | 99.6K | 60,000 | — | ↗ |
| 2022-07-01 | Strobeck Mark | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.28 | 512.0K | 400,000 | — | ↗ |
| 2022-06-07 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 93,601 | — | ↗ |
| 2022-06-07 | Radie Robert S | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 109,689 | — | ↗ |
| 2022-06-07 | RAVICH MARK H | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 278,604 | — | ↗ |
| 2022-06-07 | Nissenson Allen | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 99,488 | — | ↗ |
| 2022-06-07 | COOPER JOHN G | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 130,879 | — | ↗ |
| 2022-03-17 | TIMMINS MEGAN C. | Officer | A-Award | A | Stock Option (Right to Buy) | 37,210 | 1.37 | 51.0K | 37,210 | — | ↗ |
| 2021-08-16 | TIMMINS MEGAN C. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-17 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 68,601 | — | ↗ |
| 2021-06-17 | Radie Robert S | Director | A-Award | A | Stock Option (Right to Buy) | 72,857 | 0.90 | 65.6K | 72,857 | — | ↗ |
| 2021-06-17 | RAVICH MARK H | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 253,604 | — | ↗ |
| 2021-06-17 | Nissenson Allen | Director | A-Award | A | Stock Option (Right to Buy) | 72,857 | 0.90 | 65.6K | 72,857 | — | ↗ |
| 2021-06-17 | MCLAUGHLIN JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 72,857 | 0.90 | 65.6K | 72,857 | — | ↗ |
| 2021-06-17 | COOPER JOHN G | Director | A-Award | A | Stock Option (Right to Buy) | 72,857 | 0.90 | 65.6K | 72,857 | — | ↗ |
| 2021-05-03 | Pratt Raymond Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 112,500 | 0.94 | 105.8K | 112,500 | — | ↗ |
| 2021-05-03 | McGarry Paul E | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.94 | 70.5K | 75,000 | — | ↗ |
| 2021-05-03 | Hoffman Marc L | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.94 | 141.0K | 150,000 | — | ↗ |
| 2021-05-03 | ELLISON RUSSELL H | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2020-12-21 | Richmond David S. | 10% Owner | S-Sale | D | Common Stock | 42,450 | 1.03 | 43.7K | 1,433,309 | — | ↗ |
| 2020-12-16 | Richmond David S. | 10% Owner | S-Sale | D | Common Stock | 100,000 | 1.02 | 102.4K | 61,278 | — | ↗ |
| 2020-12-15 | Richmond David S. | 10% Owner | S-Sale | D | Common Stock | 234,145 | 1.11 | 259.1K | 3,651,658 | — | ↗ |
| 2020-12-11 | Smiley Andrea Heslin | Director | A-Award | A | Common Stock | 18,601 | 1.12 | 20.8K | 18,601 | — | ↗ |
| 2020-12-11 | Nissenson Allen | Director | A-Award | A | Common Stock | 1,488 | 0.00 | — | 24,488 | — | ↗ |
| 2020-12-07 | RAVICH MARK H | Director | J-Other | A | Common Stock | 219,905 | 1.22 | 269.2K | 219,905 | — | ↗ |
| 2020-09-15 | SKIBSTED RUSSELL | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 1.22 | 732.0K | 600,000 | — | ↗ |
| 2020-09-04 | RAVICH MARK H | Director | J-Other | D | Common Stock | 10,000 | 1.16 | 11.6K | 203,604 | — | ↗ |
| 2020-09-03 | RAVICH MARK H | Director | J-Other | D | Common Stock | 11,000 | 1.21 | 13.3K | 0 | — | ↗ |
| 2020-06-30 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 9,946 | 1.92 | 19.1K | 96,255 | — | ↗ |
| 2020-06-11 | Nissenson Allen | Director | A-Award | A | Stock Option (Right to Buy) | 34,639 | 2.04 | 70.7K | 34,639 | — | ↗ |
| 2020-06-11 | McGarry Paul E | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.04 | 204.0K | 100,000 | — | ↗ |
| 2020-05-18 | Radie Robert S | Director | A-Award | A | Stock Option (Right to Buy) | 34,024 | 2.04 | 69.4K | 34,024 | — | ↗ |
| 2020-05-18 | RAVICH MARK H | Director | A-Award | A | Stock Option (Right to Buy) | 34,024 | 2.04 | 69.4K | 34,024 | — | ↗ |
| 2020-05-18 | MCLAUGHLIN JOHN PETER | Director | A-Award | A | Common Stock | 51,800 | 0.00 | — | 86,974 | — | ↗ |
| 2020-05-18 | COOPER JOHN G | Director | A-Award | A | Common Stock | 36,000 | 0.00 | — | 55,879 | — | ↗ |
| 2020-05-14 | ELLISON RUSSELL H | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 2.08 | 4.2K | 12,050 | — | ↗ |
| 2020-04-26 | Pratt Raymond Dennis | Officer | F-InKind | D | Common Stock | 4,612 | 2.27 | 10.5K | 353,358 | — | ↗ |
| 2020-04-26 | Gupta Ajay | Officer | F-InKind | D | Common Stock | 1,758 | 2.27 | 4.0K | 574,700 | — | ↗ |
| 2020-04-17 | ELLISON RUSSELL H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 2.45 | 1.47M | 600,000 | — | ↗ |
| 2020-03-31 | Radie Robert S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-01-29 | MCLAUGHLIN JOHN PETER | Director | A-Award | A | Common Stock | 12,615 | 0.00 | — | 35,174 | — | ↗ |
| 2020-01-09 | ELLISON RUSSELL H | Director | A-Award | A | Stock Option (Right to Buy) | 16,895 | 2.32 | 39.2K | 16,895 | — | ↗ |
| 2019-11-28 | Smith Angus W. | Officer | F-InKind | D | Common Stock | 8,181 | 2.37 | 19.4K | 168,486 | — | ↗ |
| 2019-11-25 | Hoffman Marc L | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.18 | 545.0K | 250,000 | — | ↗ |
| 2019-10-07 | Gupta Ajay | Officer | F-InKind | D | Common Stock | 31,491 | 2.53 | 79.7K | 576,458 | — | ↗ |
| 2019-09-05 | MCLAUGHLIN JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 28,372 | 2.56 | 72.6K | 28,372 | — | ↗ |
| 2019-09-04 | Paul Stuart M | Director / Officer | F-InKind | D | Common Stock | 33,742 | 2.52 | 85.0K | 330,056 | — | ↗ |
| 2019-08-02 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 97 | 2.42 | 234.74 | 52,837 | — | ↗ |
| 2019-07-31 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 1,807 | 2.66 | 4.8K | 52,740 | — | ↗ |
| 2019-07-29 | Richmond Brothers, Inc. | Director | S-Sale | D | Common Stock | 179 | 3.12 | 558.48 | 161,278 | — | ↗ |
| 2019-07-25 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 29 | 3.06 | 88.70 | 77,273 | — | ↗ |
| 2019-07-24 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 2,579 | 3.13 | 8.1K | 50,933 | — | ↗ |
| 2019-07-22 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 92,707 | 2.99 | 277.2K | 161,457 | — | ↗ |
| 2019-07-19 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 68,750 | 2.89 | 198.7K | 68,750 | — | ↗ |
| 2019-07-08 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 902 | 3.05 | 2.7K | 75,699 | — | ↗ |
| 2019-07-01 | Paul Stuart M | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.97 | 29.7K | 363,798 | — | ↗ |
| 2019-06-28 | Smith Angus W. | Officer | P-Purchase | A | Common Stock | 10,000 | 3.06 | 30.6K | 176,667 | — | ↗ |
| 2019-06-24 | McGarry Paul E | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2019-06-06 | Wolin Benjamin | Director | A-Award | A | Stock Option (Right to Buy) | 22,461 | 4.15 | 93.2K | 22,461 | — | ↗ |
| 2019-06-06 | Smith Robin L | Director | A-Award | A | Stock Option (Right to Buy) | 22,461 | 4.15 | 93.2K | 22,461 | — | ↗ |
| 2019-06-06 | RAVICH MARK H | Director | A-Award | A | Common Stock | 19,759 | 0.00 | — | 356,709 | — | ↗ |
| 2019-06-06 | COOPER JOHN G | Director | A-Award | A | Common Stock | 19,879 | 0.00 | — | 19,879 | — | ↗ |
| 2019-06-06 | COLLERAN LISA N | Director | A-Award | A | Stock Option (Right to Buy) | 22,461 | 4.15 | 93.2K | 22,461 | — | ↗ |
| 2019-05-09 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 506 | 5.65 | 2.9K | 178,436 | — | ↗ |
| 2019-04-25 | Pratt Raymond Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 4.81 | 336.7K | 70,000 | — | ↗ |
| 2019-04-25 | Kull David | Officer | A-Award | A | Stock Option (Right to Buy) | 16,000 | 4.81 | 77.0K | 16,000 | — | ↗ |
| 2019-04-25 | Gupta Ajay | Officer | A-Award | A | Stock Option (Right to Buy) | 28,000 | 4.81 | 134.7K | 28,000 | — | ↗ |
| 2019-04-17 | RBI OPPORTUNITIES FUND, LLC | — | — | D | Warrants (right to buy) | 2,770,781 | 4.96 | 13.74M | 0 | — | ↗ |
| 2019-04-17 | RBI OPPORTUNITIES FUND II, LLC | — | — | D | Warrants (right to buy) | 805,664 | 4.96 | 4.00M | 0 | — | ↗ |
| 2019-03-27 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 1,554 | 5.59 | 8.7K | 177,930 | — | ↗ |
| 2019-03-25 | RBI OPPORTUNITIES FUND II, LLC | — | — | D | Common Stock | 0 | 0.00 | — | 1,655,759 | — | ↗ |
| 2019-03-15 | Paul Stuart M | Director / Officer | F-InKind | D | Common Stock | 34,327 | 5.21 | 178.8K | 353,798 | — | ↗ |
| 2018-12-21 | RAVICH MARK H | Director | J-Other | A | Common Stock | 22,200 | 0.00 | — | 336,950 | — | ↗ |
| 2018-11-28 | Smith Angus W. | Officer | A-Award | A | Stock Option (Right to Buy) | 333,333 | 3.52 | 1.17M | 333,333 | — | ↗ |
| 2018-10-15 | Richmond David S. | 10% Owner | P-Purchase | A | Warrants (right to buy) | 5,541,562 | 4.96 | 27.49M | 5,541,562 | — | ↗ |
| 2018-10-15 | RBI OPPORTUNITIES FUND, LLC | — | — | D | Common Stock | 0 | 0.00 | — | 5,541,562 | — | ↗ |
| 2018-10-07 | Gupta Ajay | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 590,949 | — | ↗ |
| 2018-09-20 | Kull David | Officer | M-Exempt | A | Common Stock | 5,000 | 3.09 | 15.5K | 7,400 | — | ↗ |
| 2018-09-04 | Paul Stuart M | Director / Officer | A-Award | A | Common Stock | 388,125 | 0.00 | — | 388,125 | — | ↗ |
| 2018-08-24 | Kull David | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 4.52 | 113.0K | 25,000 | — | ↗ |
| 2018-06-28 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 1,864 | 4.37 | 8.2K | 36,249 | — | ↗ |
| 2018-06-27 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 4,621 | 4.73 | 21.9K | 34,423 | — | ↗ |
| 2018-05-25 | Kull David | Officer | — | D | Stock Option (Right to Buy) | 5,000 | 3.09 | 15.5K | 0 | — | ↗ |
| 2018-03-19 | Wolin Benjamin | Director | A-Award | A | Stock Option (Right to Buy) | 52,501 | 5.75 | 301.9K | 52,501 | — | ↗ |
| 2018-03-19 | Smith Robin L | Director | A-Award | A | Stock Option (Right to Buy) | 38,985 | 5.75 | 224.2K | 38,985 | — | ↗ |
| 2018-03-19 | RAVICH MARK H | Director | A-Award | A | Stock Option (Right to Buy) | 38,416 | 5.75 | 220.9K | 38,416 | — | ↗ |
| 2018-03-19 | COOPER JOHN G | Director | A-Award | A | Stock Option (Right to Buy) | 39,838 | 5.75 | 229.1K | 39,838 | — | ↗ |
| 2018-03-19 | COLLERAN LISA N | Director | A-Award | A | Stock Option (Right to Buy) | 36,281 | 5.75 | 208.6K | 36,281 | — | ↗ |
| 2018-03-19 | Bagley Patrick J | Director | A-Award | A | Stock Option (Right to Buy) | 32,724 | 5.75 | 188.2K | 32,724 | — | ↗ |
| 2018-03-19 | BOYD RONALD D | Director | A-Award | A | Stock Option (Right to Buy) | 36,139 | 5.75 | 207.8K | 36,139 | — | ↗ |
| 2018-03-07 | Wolin Benjamin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-07 | COLLERAN LISA N | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-15 | Richmond David S. | 10% Owner | S-Sale | D | Common Stock | 36 | 6.53 | 235.15 | 176,376 | — | ↗ |
| 2017-12-15 | KLEMA THOMAS E | Officer | M-Exempt | D | Stock Option (Right to Buy) | 87,500 | 6.50 | 568.8K | 0 | — | ↗ |
| 2017-12-15 | CHIOINI ROBERT L | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 75,000 | 6.50 | 487.5K | 0 | — | ↗ |
| 2017-12-15 | Bagley Patrick J | Director | M-Exempt | A | Common Stock | 50,000 | 6.50 | 325.0K | 165,550 | — | ↗ |
| 2017-12-15 | BOYD RONALD D | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 6.50 | 162.5K | 0 | — | ↗ |
| 2017-09-05 | COOPER JOHN G | Director | A-Award | A | Stock Appreciation Right | 23,000 | 6.45 | 148.4K | 23,000 | — | ↗ |
| 2017-08-10 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 126 | 6.34 | 798.94 | 42,100 | — | ↗ |
| 2017-06-21 | Pratt Raymond Dennis | Officer | F-InKind | D | Common Stock | 76,230 | 7.20 | 548.9K | 317,970 | — | ↗ |
| 2017-06-21 | KLEMA THOMAS E | Officer | F-InKind | D | Common Stock | 53,273 | 7.20 | 383.6K | 670,167 | — | ↗ |
| 2017-06-21 | Gupta Ajay | Officer | F-InKind | D | Common Stock | 69,218 | 7.20 | 498.4K | 490,949 | — | ↗ |
| 2017-06-21 | CHIOINI ROBERT L | Director / Officer | F-InKind | D | Common Stock | 118,950 | 7.20 | 856.4K | 2,544,983 | — | ↗ |
| 2017-05-19 | RAVICH MARK H | — | X-InTheMoney | D | Call Option (right to buy) | 100 | 6.00 | 600.00 | 0 | — | ↗ |
| 2017-03-22 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 21,076 | 5.94 | 125.1K | 29,802 | — | ↗ |
| 2017-03-21 | Smith Robin L | Director | A-Award | A | Common Stock | 9,800 | 0.00 | — | 9,800 | — | ↗ |
| 2017-03-21 | Richmond David S. | 10% Owner | P-Purchase | A | Common Stock | 8,726 | 5.73 | 50.0K | 8,726 | — | ↗ |
| 2017-03-21 | RBI Private Investment II, LLC | — | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-03-21 | Pratt Raymond Dennis | Officer | A-Award | A | Common Stock | 68,500 | 0.00 | — | 394,200 | — | ↗ |
| 2017-03-21 | KLEMA THOMAS E | Officer | A-Award | A | Common Stock | 68,600 | 0.00 | — | 723,440 | — | ↗ |
| 2017-03-21 | Gupta Ajay | Officer | A-Award | A | Common Stock | 68,500 | 0.00 | — | 560,167 | — | ↗ |
| 2017-03-21 | CHIOINI ROBERT L | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 2,618,933 | — | ↗ |
| 2017-03-21 | Bagley Patrick J | Director | A-Award | A | Common Stock | 9,800 | 0.00 | — | 115,550 | — | ↗ |
| 2017-03-21 | BOYD RONALD D | Director | A-Award | A | Common Stock | 9,800 | 0.00 | — | 42,300 | — | ↗ |
| 2017-03-16 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,200 | 5.99 | 7.2K | 17,430 | — | ↗ |
| 2017-02-20 | Richmond David S. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 176,412 | — | ↗ |
| 2017-02-20 | RAVICH MARK H | — | — | I | Call Option (right to buy) | 8,500 | 7.00 | 59.5K | 0 | — | ↗ |
| 2016-11-11 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,500 | 5.35 | 8.0K | 24,630 | — | ↗ |
| 2016-11-09 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 6,000 | 4.72 | 28.3K | 32,355 | — | ↗ |
| 2016-11-01 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,400 | 5.92 | 8.3K | 38,355 | — | ↗ |
| 2016-10-21 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,583 | 6.10 | 9.7K | 39,755 | — | ↗ |
| 2016-10-19 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 950 | 5.94 | 5.6K | 41,338 | — | ↗ |
| 2016-09-21 | Smith Robin L | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 6.55 | 163.8K | 25,000 | — | ↗ |
| 2016-09-19 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 4,570 | 6.83 | 31.2K | 42,288 | — | ↗ |
| 2016-09-16 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 3,505 | 6.78 | 23.8K | 46,858 | — | ↗ |
| 2016-08-25 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,135 | 6.90 | 7.8K | 50,363 | — | ↗ |
| 2016-08-16 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 1,362 | 7.33 | 10.0K | 59,883 | — | ↗ |
| 2016-08-12 | HOLT KENNETH L | Director | S-Sale | D | Common Stock | 2,230 | 7.30 | 16.3K | 61,245 | — | ↗ |
| 2016-06-22 | Smith Robin L | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-19.2K
Shares Outstanding
39.41M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mark Strobeck, Ph.D. Chief Executive Officer | 566.5K | — | 612.0K | 249.7K | 453.2K | 14.0K | 1.90M | 45.46% | ↗ |
| 2 | 2025 | Megan Timmins Chief Legal Officer and Secretary | 412.0K | — | 208.7K | 158.1K | 185.4K | 14.0K | 978.2K | 37.49% | ↗ |
| 3 | 2025 | Jesse Neri Chief Financial Officer | 309.0K | — | 208.7K | 158.1K | 139.1K | 14.0K | 828.8K | 44.25% | ↗ |
| 4 | 2024 | Mark Strobeck, Ph.D. Chief Executive Officer | 566.5K | — | 139.0K | 138.4K | 453.2K | 13.8K | 1.31M | 21.16% | ↗ |
| 5 | 2024 | Megan Timmins Chief Legal Officer and Secretary | 412.0K | — | 69.5K | 69.2K | 185.4K | 13.8K | 749.9K | 18.49% | ↗ |
| 6 | 2024 | Jesse Neri Chief Financial Officer | 300.0K | — | 46.3K | 46.1K | 135.0K | 12.0K | 539.5K | 17.14% | ↗ |
| 7 | 2023 | Mark Strobeck, Ph.D. Chief Executive Officer (a) | 565.9K | — | 76.0K | 73.5K | 330.0K | 8.8K | 1.05M | 14.18% | ↗ |
| 8 | 2023 | Mark Strobeck, Ph.D. Chief Executive Officer | 565.9K | — | 76.0K | 73.5K | 330.0K | 8.8K | 1.05M | 14.18% | ↗ |
| 9 | 2023 | Megan Timmins Chief Legal Officer and Secretary | 412.0K | — | 39.1K | 35.5K | 164.8K | 8.9K | 660.3K | 11.29% | ↗ |
| 10 | 2023 | Marc Hoffman Former Chief Medical Officer | 260.2K | — | 35.2K | 31.5K | — | 159.9K | 486.8K | 13.68% | ↗ |
| 11 | 2023 | Paul McGarry Former Senior Vice President, Finance and CAO | 240.0K | — | 39.1K | 35.5K | — | 9.6K | 324.1K | 23.00% | ↗ |
| 12 | 2023 | Jesse Neri Chief Financial Officer | 57.7K | 84.0K | — | 93.5K | — | — | 235.2K | 39.77% | ↗ |
| 13 | 2023 | Jesse Neri (e) Senior Vice President, Finance | 57.7K | 84.0K | — | 93.5K | — | — | 235.2K | 39.77% | ↗ |
| 14 | 2022 | Russell Skibsted Former Chief Financial Officer (b) | 430.6K | — | — | 89.2K | — | 268.4K | 788.2K | 11.32% | ↗ |
| 15 | 2022 | Russell Ellison Former Chief Executive Officer (b) | 275.3K | — | — | — | — | 436.8K | 712.1K | 0.00% | ↗ |
| 16 | 2022 | Mark Strobeck, Ph.D. Chief Executive Officer (a) | 266.5K | — | — | 334.9K | 101.0K | 9.3K | 711.8K | 47.05% | ↗ |
| 17 | 2022 | Mark Strobeck Chief Executive Officer (a) | 266.5K | — | — | 334.9K | 101.0K | 9.3K | 711.8K | 47.05% | ↗ |
| 18 | 2022 | Megan Timmins Chief Legal Officer and Secretary | 400.0K | — | — | 89.2K | 106.4K | 11.7K | 607.3K | 14.69% | ↗ |
| 19 | 2022 | Marc Hoffman Chief Medical Officer | 401.3K | — | — | 66.9K | 106.7K | 11.7K | 586.6K | 11.40% | ↗ |
| 20 | 2022 | Marc Hoffman Former Chief Medical Officer | 401.3K | — | — | 66.9K | 106.7K | 11.7K | 586.6K | 11.40% | ↗ |
| 21 | 2021 | Raymond Pratt Former Chief Development Officer (g) | 483.6K | — | — | 71.1K | 84.6K | 14.6K | 654.0K | 10.87% | ↗ |
| 22 | 2021 | Russell Ellison Chief Executive Officer (a) | 501.1K | — | — | 126.4K | — | — | 627.5K | 20.14% | ↗ |
| 23 | 2021 | Russell Ellison Former Chief Executive Officer (b) | 501.1K | — | — | 126.4K | — | — | 627.5K | 20.14% | ↗ |
| 24 | 2021 | Russell Skibsted Chief Financial Officer | 460.0K | 128.8K | — | — | — | 10.2K | 598.9K | 0.00% | ↗ |
| 25 | 2021 | Russell Skibsted Former Chief Financial Officer (b) | 460.0K | 128.8K | — | — | — | 10.2K | 598.9K | 0.00% | ↗ |
| 26 | 2020 | Russell Ellison Chief Executive Officer (a) | 367.7K | — | 23.3K | 1.89M | 195.6K | — | 2.48M | 77.29% | ↗ |
| 27 | 2020 | Russell Ellison Chief Executive Officer (a) | 367.7K | — | 23.3K | 1.89M | 195.6K | — | 2.48M | 77.29% | ↗ |
| 28 | 2020 | Stuart Paul Former Chief Executive Officer (a) | 207.7K | — | — | — | — | 793.3K | 1.00M | 0.00% | ↗ |
| 29 | 2020 | Russell Skibsted Chief Financial Officer | 130.9K | — | — | 586.2K | — | — | 717.1K | 81.74% | ↗ |
| 30 | 2020 | Russell Skibsted Chief Financial Officer | 130.9K | — | — | 586.2K | — | — | 717.1K | 81.74% | ↗ |
| 31 | 2020 | Raymond Pratt Former Chief Development Officer (g) | 469.6K | — | — | — | 111.5K | — | 581.1K | 0.00% | ↗ |
| 32 | 2020 | Raymond Pratt Former Chief Development Officer (g) | 469.6K | — | — | — | 111.5K | — | 581.1K | 0.00% | ↗ |
| 33 | 2019 | Ajay Gupta, M.D. Chief Scientific Officer | 509.6K | — | 81.8K | 84.3K | 61.1K | — | 736.7K | 22.54% | ↗ |
| 34 | 2019 | Stuart Paul Former Chief Executive Officer (a) | 600.0K | — | — | — | — | — | 600.0K | 0.00% | ↗ |
| 35 | 2019 | Angus Smith Chief Financial Officer | 400.0K | — | — | — | 85.8K | — | 485.8K | 0.00% | ↗ |
| 36 | 2018 | Stuart Paul Former Chief Executive Officer (a) | 184.6K | 300.0K | 4.78M | 2.22M | — | — | 7.48M | 93.52% | ↗ |
| 37 | 2018 | Stuart Paul Former Chief Executive Officer (a) | 184.6K | 300.0K | 4.78M | 2.22M | — | — | 7.48M | 93.52% | ↗ |
| 38 | 2018 | Angus Smith Chief Financial Officer | 20.0K | 125.0K | 551.0K | 752.2K | — | — | 1.45M | 89.99% | ↗ |
| 39 | 2018 | Angus Smith Chief Financial Officer | 20.0K | 125.0K | 551.0K | 752.2K | — | — | 1.45M | 89.99% | ↗ |
| 40 | 2018 | Ajay Gupta, M.D. Chief Scientific Officer | 506.4K | 60.0K | 388.0K | — | — | — | 954.4K | 40.65% | ↗ |
| 41 | 2018 | Dr. Ajay Gupta Chief Scientific Officer | 506.4K | 60.0K | 388.0K | — | — | — | 954.4K | 40.65% | ↗ |
| 42 | 2018 | Robert L. Chioini(d) Former President and Chief | 387.0K | — | — | — | — | — | 389.4K | 0.00% | ↗ |
| 43 | 2017 | Robert L. Chioini President and Chief Executive Officer | 898.4K | — | 1.40M | — | — | 7.2K | 2.30M | 60.66% | ↗ |
| 44 | 2017 | Robert L. Chioini(d) Former President and Chief | 898.4K | — | 1.40M | — | — | — | 2.30M | 60.66% | ↗ |
| 45 | 2017 | Dr. Ajay Gupta Chief Scientific Officer | 506.4K | 88.6K | 390.5K | — | — | — | 985.5K | 39.62% | ↗ |
| 46 | 2017 | Dr. Raymond D. Pratt Chief Medical Officer | 460.3K | 115.1K | 390.5K | — | — | — | 965.9K | 40.42% | ↗ |
| 47 | 2017 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 442.0K | 88.4K | 391.0K | — | — | — | 921.4K | 42.44% | ↗ |
| 48 | 2016 | Robert L. Chioini President and Chief Executive Officer | 847.6K | 805.2K | — | — | — | 23.8K | 1.68M | 0.00% | ↗ |
| 49 | 2016 | Dr. Ajay Gupta Chief Scientific Officer | 486.9K | 146.1K | — | — | — | — | 633.0K | 0.00% | ↗ |
| 50 | 2016 | Dr. Raymond D. Pratt Chief Medical Officer | 442.6K | 154.9K | — | — | — | — | 597.6K | 0.00% | ↗ |
| 51 | 2016 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 417.0K | 166.8K | — | — | — | — | 583.8K | 0.00% | ↗ |
| 52 | 2015 | Robert L. Chioini Chairman, President and Chief Executive Officer | 847.6K | 805.2K | 2.67M | 3.50M | — | 22.6K | 7.85M | 78.67% | ↗ |
| 53 | 2015 | Robert L. Chioini President and Chief Executive Officer | 847.6K | 805.2K | 2.67M | 3.50M | — | 22.6K | 7.85M | 78.67% | ↗ |
| 54 | 2015 | Dr. Ajay Gupta Chief Scientific Officer | 486.9K | 146.1K | 1.36M | 972.3K | — | — | 2.96M | 78.64% | ↗ |
| 55 | 2015 | Dr. Raymond D. Pratt Chief Medical Officer | 442.6K | 154.9K | 1.36M | 972.3K | — | — | 2.93M | 79.59% | ↗ |
| 56 | 2015 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 417.0K | 166.8K | 1.23M | 972.3K | — | — | 2.79M | 79.08% | ↗ |
| 57 | 2014 | Robert L. Chioini Chairman, President and Chief Executive Officer | 706.3K | 635.7K | 2.79M | 4.36M | — | 20.1K | 8.51M | 84.00% | ↗ |
| 58 | 2014 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 386.1K | 115.8K | 1.33M | 1.43M | — | — | 3.26M | 84.59% | ↗ |
| 59 | 2014 | Dr. Ajay Gupta Chief Scientific Officer | 450.9K | 135.3K | 1.42M | 1.23M | — | — | 3.24M | 81.90% | ↗ |
| 60 | 2014 | Dr. Raymond D. Pratt Chief Medical Officer | 409.9K | 131.2K | 1.42M | 1.23M | — | — | 3.19M | 83.06% | ↗ |
| 61 | 2013 | Robert L. Chioini Chairman, President and Chief Executive | 588.6K | 353.2K | 394.0K | 898.8K | — | 21.0K | 2.26M | 57.32% | ↗ |
| 62 | 2013 | Robert L. Chioini Chairman, President and Chief Executive Officer | 588.6K | 353.2K | 394.0K | 898.8K | — | 21.0K | 2.26M | 57.32% | ↗ |
| 63 | 2013 | Dr. Ajay Gupta Chief Scientific Officer | 413.6K | 115.8K | 295.5K | — | — | — | 1.36M | 21.66% | ↗ |
| 64 | 2013 | Dr. Raymond D. Pratt(e) Chief Medical Officer | 391.8K | 108.1K | 295.5K | 539.3K | — | — | 1.33M | 62.55% | ↗ |
| 65 | 2013 | Dr. Raymond D. Pratt Chief Medical Officer | 391.8K | 108.1K | 295.5K | — | — | — | 1.33M | 22.14% | ↗ |
| 66 | 2013 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 351.0K | 105.3K | 236.4K | 359.5K | — | — | 1.05M | 56.63% | ↗ |
| 67 | 2012 | Robert L. Chioini Chairman, President and Chief Executive Officer | 545.0K | 136.3K | 945.0K | 1.45M | — | 20.3K | 3.10M | 77.33% | ↗ |
| 68 | 2012 | Robert L. Chioini Chairman, President and Chief Executive | 545.0K | 136.3K | 945.0K | 1.45M | — | 20.3K | 3.10M | 77.33% | ↗ |
| 69 | 2012 | Dr. Ajay Gupta Chief Scientific Officer | 383.0K | 95.8K | 708.8K | — | — | — | 2.05M | 34.60% | ↗ |
| 70 | 2012 | Dr. Ajay Gupta(e) Chief Scientific Officer | 383.0K | 95.8K | 708.8K | 860.7K | — | — | 2.05M | 76.63% | ↗ |
| 71 | 2012 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 325.0K | 81.3K | 567.0K | 566.7K | — | — | 1.54M | 73.62% | ↗ |
| 72 | 2012 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 325.0K | 81.3K | 567.0K | 566.7K | — | — | 1.54M | 73.62% | ↗ |
| 73 | 2012 | Dr. Raymond D. Pratt(e) Chief Medical Officer | 212.3K | 49.8K | — | 775.8K | — | — | 1.04M | 74.75% | ↗ |
| 74 | 2012 | Dr. Raymond D. Pratt Chief Medical Officer | 212.3K | 49.8K | — | — | — | — | 1.04M | 0.00% | ↗ |
| 75 | 2012 | Dr. Raymond D. Pratt(f) | 212.3K | 49.8K | — | 775.8K | — | — | 1.04M | 74.75% | ↗ |
| 76 | 2011 | Robert L. Chioini Chairman, President and Chief Executive Officer | 505.0K | 126.3K | — | 1.26M | — | 20.7K | 1.91M | 65.92% | ↗ |
| 77 | 2011 | Robert L. Chioini Chairman, President and Chief Executive | 505.0K | 126.3K | — | 1.26M | — | 20.7K | 1.91M | 65.92% | ↗ |
| 78 | 2011 | Dr. Ajay Gupta(e) Chief Scientific Officer | 355.0K | 88.8K | — | 756.5K | — | — | 1.20M | 63.03% | ↗ |
| 79 | 2011 | Dr. Ajay Gupta (e) Chief Scientific Officer | 355.0K | 88.8K | — | 756.5K | — | — | 1.20M | 63.03% | ↗ |
| 80 | 2011 | Dr. Ajay Gupta Chief Scientific Officer | 355.0K | 88.8K | — | — | — | — | 1.20M | 0.00% | ↗ |
| 81 | 2011 | Thomas E. Klema Secretary, Treasurer and Chief Financial Officer | 301.0K | 75.3K | — | 504.3K | — | — | 880.6K | 57.27% | ↗ |
| 82 | 2011 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 301.0K | 75.3K | — | 504.3K | — | — | 880.6K | 57.27% | ↗ |
| 83 | 2011 | Vice President of Drug Development Medical Affairs | 78.1K | — | — | 498.2K | — | — | 576.2K | 86.45% | ↗ |
| 84 | 2011 | Dr. Richard C. Yocum (g) Former Vice President of Drug Development Medical Affairs | 217.8K | — | — | — | — | — | 217.8K | 0.00% | ↗ |
| 85 | 2010 | Robert L. Chioini Chairman, President and Chief Executive Officer | 495.0K | 198.8K | 586.2K | 1.01M | — | 20.2K | 2.31M | 69.12% | ↗ |
| 86 | 2010 | Dr. Ajay Gupta(e) Chief Scientific Officer | 348.0K | 87.0K | 439.6K | — | — | — | 1.40M | 31.33% | ↗ |
| 87 | 2010 | Dr. Ajay Gupta (e) Chief Scientific Officer | 348.0K | 87.0K | 439.6K | 528.8K | — | — | 1.40M | 69.00% | ↗ |
| 88 | 2010 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 295.0K | 73.8K | 351.7K | 475.6K | — | — | 1.20M | 69.17% | ↗ |
| 89 | 2010 | Dr. Richard C. Yocum (g) Former Vice President of Drug Development Medical Affairs | 298.0K | — | — | 328.8K | — | — | 626.8K | 52.46% | ↗ |
| 90 | 2010 | Dr. Richard C. Yocum (e) Vice President of Drug Development Medical Affairs | 298.0K | — | — | — | — | — | 626.8K | 0.00% | ↗ |
| 91 | 2009 | Robert L. Chioini Chairman, President and Chief Executive Officer | 465.0K | 116.3K | — | 934.5K | — | 22.0K | 1.54M | 60.77% | ↗ |
| 92 | 2009 | Dr. Ajay Gupta (e) Chief Scientific Officer | 159.3K | 38.0K | — | — | — | — | 1.03M | 0.00% | ↗ |
| 93 | 2009 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 275.0K | 68.8K | — | 519.2K | — | — | 862.9K | 60.16% | ↗ |
| 94 | 2009 | Dr. Richard C. Yocum (e) Vice President of Drug Development Medical Affairs | 235.2K | 58.0K | — | — | — | — | 473.8K | 0.00% | ↗ |
| 95 | 2009 | Dr. Richard C. Yocum (g) Former Vice President of Drug Development Medical Affairs | 235.2K | 58.0K | — | 180.5K | — | — | 473.8K | 38.10% | ↗ |
| 96 | 2008 | Robert L. Chioini Chairman, President and Chief Executive Officer | 465.0K | 40.0K | 309.0K | — | — | 18.8K | 1.47M | 21.08% | ↗ |
| 97 | 2008 | Robert L. Chioini President, Chief Executive Officer, Chairman of the Board and Director | 465.0K | 40.0K | 11.9K | — | — | 18.8K | 992.7K | 1.20% | ↗ |
| 98 | 2008 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 275.0K | 20.0K | 154.5K | — | — | — | 602.1K | 25.66% | ↗ |
| 99 | 2007 | Robert L. Chioini Chairman, President and Chief Executive Officer | 275.0K | 40.0K | — | — | — | 19.9K | 1.44M | 0.00% | ↗ |
| 100 | 2007 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 160.2K | 25.0K | — | — | — | — | 957.7K | 0.00% | ↗ |
| 101 | 2007 | Robert L. Chioini Chief Executive Officer, Chairman of the Board and Director | 275.0K | 40.0K | — | — | — | 19.9K | 353.2K | 0.00% | ↗ |
| 102 | 2007 | Robert L. Chioini President, Chief Executive Officer, Chairman of the Board and Director | 275.0K | 40.0K | — | — | — | 19.9K | 353.2K | 0.00% | ↗ |
| 103 | 2006 | Robert L. Chioini Chief Executive Officer, Chairman of the Board and Director | 275.0K | — | — | — | — | 19.3K | 294.3K | 0.00% | ↗ |
| 104 | 2006 | Robert L. Chioini President, Chief Executive Officer, Chairman of the Board and Director | 275.0K | — | — | — | — | 19.3K | 294.3K | 0.00% | ↗ |
| 105 | 2006 | Thomas E. Klema Chief Financial Officer, Secretary and Treasurer | 160.2K | — | — | — | — | — | 160.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Strobeck | President, Chief Executive Officer & Director | 1M | — |
| Megan C. Timmins | Executive Vice President, Chief Legal Officer & Secretary | 611.4K | female |
| Jesse Neri | Senior Vice President & Chief Financial Officer | 447.0K | male |
| Heather H. Hunter | Senior Vice President & Chief Operating Officer | — | female |
| Nicholas Fanslau | Controller & Principal Accounting Officer | — | male |
| Timothy T. Chole | Senior Vice President & Chief Commercial Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RMTI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
